National Institute of Neurological Disorders and Stroke (NINDS)

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, National Institute of Neurological Disorders and Stroke (NINDS) sits in the top decile of US sponsors by registered trial count (#61 of 15,742 sponsors by registered trial count).

567 total trials 48 currently recruiting 467 completed early-phase tilt top decile by trial count

National Institute of Neurological Disorders and Stroke (NINDS): 567 sponsored US clinical trials, 48 recruiting.

National Institute of Neurological Disorders and Stroke (NINDS) sponsors 567 registered US clinical trials on ClinicalTrials.gov, 48 of them currently recruiting, and 467 completed. 16 of these trials are in Phase 3-4 (later-stage) and 158 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 23 trials.

Top-decile sponsor footprint

National Institute of Neurological Disorders and Stroke (NINDS) ranks in the top decile of sponsors by registered trial count (#61 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 70/100

467 of 508 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

567 total, page 3 of 12

COMPLETED Phase 1

Botulinum Toxin for Pelvic Pain in Women With Endometriosis

NCT01553201
COMPLETED Phase 2

Efficacy of Levetiracetam in Oromandibular and Cranial Dystonia

NCT02199509
TERMINATED

Clinical Autonomic Disorders: A Training Protocol

NCT02154009
COMPLETED Phase 1

Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)

NCT02108002
COMPLETED Phase 2

Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency

NCT02019667
TERMINATED

fMRI Neurofeedback for Motor Rehabilitation

NCT02089776
TERMINATED

Depotentiation in People With Focal Hand Dystonia

NCT02106936
COMPLETED Phase 1

Pilot Trial of Botulinum Toxin and Occupational Therapy for Writer's Cramp

NCT02015039
COMPLETED

Functional Brain Imaging in Healthy Volunteers to Study Cognitive Functions

NCT01974427
COMPLETED Phase 1

Manganese-Enhanced Magnetic Resonance Imaging in Healthy Volunteers and People With Multiple Sclerosis

NCT01326715
COMPLETED

Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation

NCT01925196
COMPLETED Early Phase 1

Raltegravir for HAM/TSP

NCT01867320
TERMINATED Phase 1

Effects of Exercise on Memory in Healthy and Brain-Injured Individuals

NCT01939769
TERMINATED

Cerebrospinal Fluid Collection and Repository Storage

NCT01862107
COMPLETED

The Effects of Repetitive Paired Associative Stimulation in Dystonia

NCT01888926
TERMINATED

A Study of Movement Disorders Using the QMAT At-Home Testing Device

NCT01905839
COMPLETED Early Phase 1

Exercise Education for Adults With Seizure Disorders

NCT01856335
COMPLETED

Imaging Studies of Cognitive Impairment in Parkinson s Disease

NCT01862744
TERMINATED

Natural History of Optic Neuritis

NCT01851434
COMPLETED Phase 1

AAV2-GDNF for Advanced Parkinson s Disease

NCT01621581
TERMINATED

Transcranial Magnetic Stimulation for Focal Hand Dystonia

NCT01792336
COMPLETED NA

Treatment of Functional Movement Disorders With Psychotherapy

NCT01778517
COMPLETED NA

Effects of Transcranial Magnetic Stimulation on Object Recognition

NCT01747200
TERMINATED Phase 2

Acetyl Hexapeptide-8 for Blepharospasm

NCT01750346
COMPLETED

Relating Genetic and Environmental Risk Scores to Multiple Sclerosis Susceptibility

NCT01617395
COMPLETED

Brain P-gp and Inflammation in People With Epilepsy

NCT01663545
COMPLETED

The Effects of Chronic Exposure to Low-Level Blasts

NCT01524822
COMPLETED

Taurine Therapy for SSADH Deficiency

NCT01608178
COMPLETED

Validating a New Writer s Cramp Scale

NCT01579266
TERMINATED

Infants With Spinal Muscular Atrophy Type I

NCT01547871
COMPLETED

Studying Motor Neuron Tests

NCT01517087
COMPLETED

Imaging Biomarkers in Parkinson s Disease

NCT01496599
COMPLETED

Service Member Fatigue and Lack of Motivation Following Concussion

NCT01496586
TERMINATED Phase 2

Buspirone Therapy for Localized Epilepsy

NCT01496612
COMPLETED Phase 1

Octanoic Acid for Essential Tremor

NCT01468948
COMPLETED Early Phase 1

Effects of Hormone Stimulation on Brain Scans for Cushing s Disease

NCT01459237
COMPLETED

Studying Skeletal Muscle, Heart, and Diaphragm Imaging in Boys With Duchenne Muscular Dystrophy

NCT01451281
COMPLETED Phase 1

Effect of Functional Exercise in Patients With Spinal Bulbar Muscular Atrophy

NCT01369901
TERMINATED

Brain Areas Involved in Sound and Spoken Word Memory

NCT01375595
COMPLETED

Structural and Functional Neuroimaging Studies of Combat Veterans

NCT01296126
TERMINATED Phase 2

PRX-00023 Therapy in Localization-Related Epilepsy

NCT01281956
COMPLETED Phase 1

Intravenous Norepinephrine for Orthostatic Hypotension

NCT01285908
TERMINATED

The Effect of Transcranial Magnetic Stimulation on Learning With Reward in Healthy Humans

NCT01260740
COMPLETED

Evaluation, Pathogenesis, and Outcome of Subjects With or Suspected Traumatic Brain Injury

NCT01132937
COMPLETED

Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients

NCT01222728
TERMINATED Phase 1

Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)

NCT01212094
COMPLETED

Ethanol Response in Essential Tremor: Clinical and Neurophysiological Correlates

NCT01200966
COMPLETED

Neural Dynamics and Connectivity in Response Inhibition and Traumatic Brain Injury

NCT01194661
COMPLETED

Oxidative Stress in Motor Neuron Disease: COSMOS Add-On Study

NCT01143428
COMPLETED Phase 1

Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS)

NCT01143441
← Previous Page 3 of 12 Next →

Phase Distribution

PhaseTrial count
Phase 1 80
Phase 2 78
Phase 3 11
Phase 4 5

Therapeutic Areas

Healthy 23
Cerebrovascular Accident 9
Epilepsy 9
Parkinson's Disease 8
Parkinson Disease 8
Multiple Sclerosis 8
Focal Dystonia 7
Normal Physiology 7
Stroke 7
Motor Neuron Disease 6

What is open in the National Institute of Neurological Disorders and Stroke (NINDS) pipeline

48 recruiting of 567 indexed (8% open); 467 completed (82%).

Phase mix: 16 late (III/IV) vs 158 early (I/II) (early-phase heavy).

Top condition: Healthy (23 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

National Institute of Neurological Disorders and Stroke (NINDS): open-pipeline peers nationwide

Peers matched on 567 registered trials and 8% open enrollment, not the therapeutic-area sidebar.

National Institute of Neurological Disorders and Stroke (NINDS) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600 5%10%15%20%25% Total trials Recruiting share National Institute of Neurological Disorders and Stroke (NINDS)Children's Hospital Medical Center, CincinnatiUniversity of Maryland, BaltimoreAmgenMerck Sharp & DohmeNational Jewish HealthACADIA PharmaceuticalsTexas Tech University Health Sciences Center, El PasoBoehringer Ingelheim
National Institute of Neurological Disorders and Stroke (NINDS) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

National Institute of Neurological Disorders and Stroke (NINDS) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 567 trials (± recruiting share)

Sponsors near 8% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this National Institute of Neurological Disorders and Stroke (NINDS) page

567 registered trials is a research-attention snapshot, not an endorsement of National Institute of Neurological Disorders and Stroke (NINDS) or any single study.

  • 48 of National Institute of Neurological Disorders and Stroke (NINDS)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Healthy is the condition National Institute of Neurological Disorders and Stroke (NINDS) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

National Institute of Neurological Disorders and Stroke (NINDS) pipeline card: 567 registered trials from official public datasets.Report a data error.